The False Claims Act (the "FCA”) has not been significantly amended since 1986. In the past several years, however, the federal judiciary has decided a series of cases narrowly interpreting the terms of the FCA, increasing hurdles to successful prosecution of false claims cases.

Earlier this year,  the President signed into law the Fraud Enforcement and recovery Act of 2009 ("FERA"),which will impose sweeping changes to the federal False Claims Act (“FCA”).   This law has significantly expanded the scope of FCA liability.  In addition it provides for new investigative tools and will make it easier for qui tam relators to bring and maintain FCA suits.

These changes will have a significant impact on medical device manufacturers and pharmaceutical companies.

This webinar addresses the significant  components of the law while also investigating how these changes are currently impacting the life sciences industry in regards to compliance and the possibility of future suits under the FCA.

Attend this event to:

• Identify the significant changes to the FCA
• Liability Provisions
• Procedural Provisions
• Elimination of the Presentment Requirement
• Elimination of the Intent Requirement
• Extension of Liability to Claims Made on Funds to which the United States does not Hold Title
• Extension of Liability for “Reverse” False Claims
• Understand how these changes are impacting the life sciences industry

For more information regarding registration for this event, please visit CBI's website